Overview
ONC market data
Price History
ONC price chart
Valuation & Profitability
- P/E (TTM)
- 88.12 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.98 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.33 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.1% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 7.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $205.51 – $346.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $278.7B · P/B 8.68 · P/S 6.84.
Company News
BeOne Medicines And Revolution Medicines Form Clinical Collaboration To Evaluate Drug Combinations Using Select Clinical-Stage Oncology Assets From BeOne With Any Of Revolution’s Four Clinical RAS(ON) InhibitorsBenzinga · Aug 10, 2026, 10:10 AM
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454Benzinga · Aug 6, 2026, 7:34 PM
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450Benzinga · Aug 6, 2026, 5:06 PM
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418Benzinga · Aug 6, 2026, 3:53 PM
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430Benzinga · Aug 6, 2026, 2:09 PM
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405Benzinga · Aug 6, 2026, 1:02 PM
BeiGene shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.Benzinga · Aug 5, 2026, 11:40 AM
BeOne Medicines Raises FY2026 Sales Guidance from $6.300B-$6.500B to $6.600B-$6.800B vs $6.479B EstBenzinga · Aug 5, 2026, 10:00 AM
BeiGene Q2 Adj. EPS $3.84 Beats $1.44 Estimate, Sales $1.705B Beat $1.591B EstimateBenzinga · Aug 5, 2026, 10:00 AM
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425Benzinga · Jul 23, 2026, 6:36 PM